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Abstract
Background: There is limited knowledge of Chronic Kidney Disease (CKD) among high risk
populations, especially in the developing countries. We report our study of testing for CKD in at-
risk subjects.
Methods: In a cross-sectional study, 527 people from primary and secondary health care areas in
the city of Kinshasa were studied from a random sample of at-risk out-patients with hypertension,
diabetes, obesity, or HIV+. We measured blood pressure (BP), blood glucose level, proteinuria,
body mass index, and estimated glomerular filtration rate (eGFR by MDRD equation) using
calibrated creatinine levels based on one random measurement. The associations between health
characteristics, indicators of kidney damage (proteinuria) and kidney function (<60 ml/min/1.73 m2)
were also examined.
Results: The prevalence of CKD in this study was 36%, but only 12% were aware of their
condition. 4% of patients had stage 1 CKD, 6% stage 2, 18% stage 3, 2% stage 4, and 6% had stage
5. 24 hour quantitative proteinuria (>300 mg/day) was found in 19%. In those with the at-risk
conditions, the % of CKD was: 44% in patients with hypertension, 39% in those with diabetes; 16%
in the obese and 12% in those who were HIV+. 82% of those with a history of diabetes had elevated
serum glucose levels at screening (≥ 126 mg/dl). Only 6% of individuals with hypertension having
CKD had reduced BP to lower than 130/80 mmHg. In multivariate analysis, diabetes, proteinuria
and hypertension were the strongest determinants of CKD 3+.
Conclusion: It appears that one out of three people in this at-risk population has undiagnosed
CKD and poorly controlled CKD risk factors. This growing problem poses clear challenges to this
developing country. Therefore, CKD should be addressed through the development of
multidisciplinary teams and improved communication between traditional health care givers and
nephrology services. Attention to CKD risk factors must become a priority.
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Background
Chronic Kidney Disease (CKD) is a worldwide health
problem [1]. Indeed, the incidence and prevalence of
CKD has increased in recent years in both developed and
developing countries [2] including in Sub-Saharan Africa
(SSA) [3]. In SSA, CKD affects mainly young adults in
their productive years and is a significant cause of death
[3,4]. This may occur by death from kidney failure, and
also by cardiovascular deaths, which are increased in
those with CKD. Major contributory factors for this omi-
nous picture include late referral to hospital, limited renal
replacement therapy (RRT), limited capacity of health
workers for CKD detection and prevention, and poor
awareness of kidney disease in the community [3,5,6].
This situation prompted the International Society of
Nephrology Commission for the Global Advancement of
Nephrology (ISN COMGAN) to make the fight against
CKD one of its priorities, by promoting awareness, early
detection, and effective treatment [7].
In our recent survey [4] in the general population of Kin-
shasa, the capital of the Democratic Republic of Congo
(DRC) the prevalence of early stage CKD was 10 times
greater than that of stage 5 CKD or end stage renal disease
(ESRD). Thus, while severe CKD can result in progressive
kidney failure, the effects of less-severe CKD are quantita-
tively more important. Although cumulative evidence
shows that early detection and treatment prevents or
delays some of its adverse outcomes [8-11], the majority
of subjects at early stages of CKD are undiagnosed and
under-treated in SSA [6]. Indeed, because of the scarcity of
financial resources and shortage of manpower, CKD pre-
vention programs are either rudimentary or virtually non-
existent in the developing world [12].
Furthermore, attention to health problems in SSA is usu-
ally been focused on infectious diseases, rather than on
chronic non-communicable disease (CND) such as CKD.
Screening of specific groups for CKD, such as those with
known diabetes (DM) or with hypertension (HTN), may
be more cost effective than screening the general popula-
tion [13]. But, the benefits of targeted screening of
patients with DM and HTN versus screening of general
population are debatable [14]. A non validated Modifica-
tion of Diet in Renal Disease (MDRD) study equation in
Black Africans, would probably lead to an over or under-
estimation of CKD prevalence in Sub-Saharan popula-
tion.
Nonetheless, since we found an increasing prevalence of
CKD risk factors such as HTN, DM, and obesity in Kin-
shasa [4], along with the co-occurrence of human immu-
nodeficiency virus (HIV) infection and HIV-associated
renal diseases [15], it seemed reasonable to target screen-
ing on these groups [16]. The objective of this survey was
to experiment early detection of a large numbers of previ-
ously unidentified persons with or at high risk for CKD. In
addition, we determined the prevalence of CKD across
selected risk factors and according to the level of kidney
function within groups. Finally, socio-demographic fea-
tures and clinical parameters of this at-risk group were
assessed.
Methods
Study design and population
The present cross-sectional study is the second part of a
larger ongoing study of CKD and associated risk factors
termed "Prévalence, détection précoce et prévention des
maladies rénales chroniques et facteurs de risque associés
(PDMRA) en République Démocratique du Congo ". The
present survey was done between January 9 and May 25,
2007.
Screening sites included primary (n = 9) and secondary
health care (n = 4) chosen at random among networks of
healthcare areas existing in the city of Kinshasa. The
choice of the networks was based on the following crite-
ria: a high number of the patients at-risk of CKD attending
the centre, agreement of the authorities and availability of
the health workers in these centres to select the subjects as
well as to accommodate the research workers. PDMRA
screening was conducted by a mobile research team com-
posed of nephrologists, nurses and laboratory techni-
cians. Primary care is a term used to define the activity of
a health care provider who acts as a first point of consul-
tation for all patients, while secondary health care
includes dispensation of the care, hospital admissions
and quality control of the structures of primary care.
Eligibility criteria for screening were age of 18 years or
older and a personal history of HTN, DM, obesity or HIV
infection, or first degree relative with kidney disease.
Screening Examinations and data collection
Knowing that 12.4% of adults have CKD in Kinshasa [4],
approximately 473 subjects were required to reach that
prevalence with error estimate of 3% [17]. Of an intended
sample size of 550, 527 persons (291 in primary care and
236 in secondary care) agreed to participate. But, for three
of them, the sample of serum was not properly handled.
All participants provided informed written consent before
enrolment. They were examined by the research team,
which recorded information on demographics, diet,
smoking, alcohol consumption, use of indigenous herbal
drugs, and birth weight knowledge. Data about first
degree family relatives and medical history for kidney dis-
ease, HTN, DM and current treatment were also recorded.BMC Nephrology 2009, 10:18 http://www.biomedcentral.com/1471-2369/10/18
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Body weight, height and waist circumference were meas-
ured. HTN, DM, obesity and HIV infection had been diag-
nosed during past patient visits. These diagnoses were
confirmed in writing. All HIV participants except twelve
received standard weight-based dosages of highly active
antiretroviral therapy (HAART), but medications were not
adjusted for kidney function. They were initiated on sta-
vudine plus lamivudine with either nevirapine (82%) or
efavirenz (4%).
Blood pressure (BP) was measured twice in the right or left
arm using a calibrated sphygmomanometer (WelchAllyn,
Germany) at heart level. The subjects were allowed to
relax for 5 minutes in a sitting position before determina-
tion of blood pressure.
HTN was defined as a systolic blood pressure ≥ 140
mmHg or diastolic blood pressure ≥ 90 mmHg and/or
concomitant use of antihypertensive medications by self-
report [18].
BP was categorized according to the Seventh Joint
National Committee Report on Detection, Evaluation and
Treatment of High Blood Pressure [18]. The categories
were as follows:
- normal, < 120 and < 80 mmHg,
- prehypertension, 120–139 or 80–89 mm Hg;
- stage 1, 140–159 or 90–99 mm Hg;
- stage 2, ≥ 160 or ≥ 100 mm Hg.
The body mass index was calculated from the measured
weight (in kilograms) and height (in meters) and was cat-
egorized as not obese (< 25 kg/m2), overweight (25 to
29.9 kg/m2) or obese (≥ 30 kg/m2) according to the 2000
WHO criteria [19].
The diagnosis of DM was established after two fasting glu-
cose values of ≥ 126 mg/dl using fingertip blood (Accu-
trend glucometer) and/or concomitant use of antidiabetic
medications. DM was classified as type 2 or type 1 by clin-
ical features as follows. Illness starting after age 40 years,
the presence of chronic complications at onset, and an
absence of ketones determined the diagnosis of type 2 dia-
betes. On the other hand, illness onset before or at age 30,
and typical clinical signs (weight loss, asthenia, polyuria,
polydipsia) determined the diagnosis of type 1 diabetes.
The participants provided a urine sample to detect pro-
teins by urinary strips '(Combur 7-test)". Female subjects
were instructed to void a random urine specimen, remote
from menstrual periods. If positive with dipstick protein
of 3+ (n = 102), measurement of 24-hour urinary protein
was obtained (n = 99). Because ratio of albumin to creat-
inine (ACR) was not available and because urine dipstick
provides only a semi-quantitative estimation of proteinu-
ria and has imperfect accuracy in diagnosis of persistent
proteinuria, kidney damage in stage 1 and 2 CKD in our
study was identified as 24-hour urinary protein ≥ 300 mg
per day. Serum creatinine and 24-hour quantitative pro-
teinuria were carried out according to the kinetic Jaffe
(semi-automated polyphotometer Visual Biomérieux)
and Esbach methods, respectively. These tests were per-
formed in the laboratory of the Belgian medical centre of
Kinshasa ''CMK". For estimated Glomerular Filtration
Rate (eGFR) determination, the abbreviated equation
from the MDRD study was used. We calibrated the creati-
nine results measured with the Jaffe method against a
traceable isotope dilution mass spectrometry (IDMS)
enzymatic method (creatinine +, Roche enzymatic diag-
nostics) as described [4]. Recalibrated serum creatinine
values were thereafter computed for each participant and
the new MDRD study equation was used for estimation of
the eGFR as 175 × (serum creatinine level [(mg/dl)])-1.154
× (age [(years)])-0.203 [20]. For women and for blacks (all
patients in our study), the product of this equation was
multiplied by correction factor of 0.742 and 1.21, respec-
tively.
The K/DOQI guidelines [21] for definition and classifica-
tion of CKD were used in the present study. The CKD
stages are defined as follows: stage 1, proteinuria ≥ 300 mg
per day with an eGFR higher than 90 ml/min/1.73 m2;
stage 2, proteinuria ≥ 300 mg per day with an eGFR of 60
to 89 ml/min/1.73 m2; stage 3, an eGFR of 30 to 59 ml/
min/1.73 m2; stage 4, an eGFR of 15 to 29 ml/min/1.73
m2; and stage 5, an eGFR <15 ml/min/1.73 m2.
The term chronic renal failure or CKD 3+ refers to an
eGFR< 60 ml/min/1.73 m2. The term "all stages of CKD"
includes both kidney damage (early stage of CKD, 1 and
2) and chronic renal failure (CKD 3 or worse).
Statistical analysis
Results are presented as number and percentage or mean
± SD. 2-sample Student's t test and chi-squares were used
for comparison of means and proportions, where appro-
priate.
The outcome under analysis was the presence of CKD,
defined as above. Exposure variables that were considered
included gender, age, smoking, herbal drugs use, BMI,
DM, pulse pressure, family history of kidney disease (FH-
KD), HTN, and HIV infection. The crude (unadjusted)
relationships between the exposure variables and the pres-
ence or absence of CKD were examined in univariate
logistic regression analyses. Multivariate stepwise logisticBMC Nephrology 2009, 10:18 http://www.biomedcentral.com/1471-2369/10/18
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regression analysis was then done to evaluate the simulta-
neous effects of various exposure variables, with adjust-
ment for the potential confounding effects of other
factors. The above approaches were applied separately for
CKD stage 3+ and for proteinuria.
A multiple linear regression model was used to determine
the independent association between the reduction of an
eGFR < 60 ml/min/1.73 m2 and continuous variables such
as age, duration of DM, duration of HTN, BP, and BMI.
Except chi-squares, all data analysis and calculations were
performed by using a standard statistical package (SPSS
Inc, Chicago, IL version 13.0, 2004). Chi-squares were
made in the dialog box using medcalc version 9.1.01,
2005. A P value < 0.05 indicated statistical significance.
All rules of confidentiality were complied with, including
collection of information and physical examination. This
study was approved by ethics committee of the Provincial
Medical Inspection of Kinshasa.
Results
A. Characteristics of the study population
Sociodemographic characteristics of the participants are
listed in Table 1. The age range was between 18–90 years
old (mean 54 ± 15, median 55). Some statistically signif-
icant differences between male and female subjects were
observed.
B. CKD according to health care level
The overall prevalence of CKD stage 1–5 was 36% (95%
CI, 36.0 to 36.4) (Table 2) and was higher in males than
in females, being 40% versus 34%, respectively. Of these
190 subjects with CKD, 14% had reduced eGFR MDRD
equation < 60 ml/min/1.73 m2 (CKD stage 3 or more).
However, only twenty four of those with CKD (12%) were
aware of their condition. 24 h quantitative proteinuria ≥
300 mg was detected in 19% of the studied population.
Although all stages of CKD were found in both levels of
health care, 9 patients (3%) and 24 patients (8%) in pri-
mary care and, 13 patients (6%) and 8 patients (3%) in
secondary care had CKD stage 1 or 2, respectively. Thus,
CKD stage 2 was more prevalent in primary care com-
pared to secondary care (P < 0.05). In contrast, CKD stage
4 and 5 was more frequent in secondary health care than
it was in primary care (P < 0.001). Most of patients with
stage 5 CKD died quickly from uraemia because of lack of
dialysis.
In addition, the prevalence of CKD among subjects at-risk
according to K/DOQI stage is shown in figure 1. In those
with the at-risk conditions, the prevalence of CKD was:
45% in patients with DM and HTN, 26% in patients with
HTN, 16% in the obese and 12% in those who were HIV+.
In persons having FH-KD, CKD was found in 8%. Table 3
shows the 24-hour quantitative urine protein, dipstick
abnormalities in the urine (proteinuria, pyuria and hema-
turia) and elevated creatinine (men > 1.6 mg/dl and
women > 1.4 mg/dl) according to K/DOQI stage.
In the 82 people with HIV, quantitative proteinuria at
more than 300 mg/day was observed in five subjects; five
others had CKD stage 3+.
Table 1: Population characteristics.
Clinical features Males
N = 229
Females
N = 298
Total
N = 527
P
Age mean ± SD (yr) 55.3 ± 15.3 52.8 ± 14.9 53.9 ± 15.5 0.05
Age range n (%)
-18 to 43 yr 53 (23.1) 83 (27.9) 136 (25.8) 0.25
-44 to 55 yr 52 (22.7) 83 (27.9) 135 (25.6) 0.20
-56 to 67 yr 69 (30.1) 78 (26.2) 147 (27.9) 0.37
-> 67 yr 55 (24.0) 54 (18.1) 109 (20.7) 0.12
Hypertension n (%) 129 (56.3) 175 (58.7) 304 (58.2) 0.62
Diabetes n (%) 125 (54.5) 162 (54.4) 287 (54.5) 0.76
- Type 1 8 (6.4) 6 (3.7) 14 (4.9) 0.4
- Type 2 117 (93.6) 156 (96.3) 273 (95.1) 0.4
Obesity n (%) 14 (6.1) 71 (23.8) 85 (16.1) < 0.0001
HIV infection* n (%) 22 (32.4) 60 (49.6) 82 (43.4) 0.03
FH-KD first degree* n (%) 13 (7. 3) 25 (11.7) 38 (9.7) 0.12
History of Kidney disease n (%) 15 (6.8) 9 (3.1) 24 (4.6) 0.07
Smoking currently n (%) 28 (12.3) 10 (3.4) 38 (7.3) 0.0002
Herbal remedy use n (%) 58 (25.4) 37 (12.5) 95 (18.2) 0.0002
Low educational level** 65 (29.0) 162 (55.5) 227 (44.0) < 0.0001
Values expressed as numbers and proportions in parentheses or mean ± SD, as appropriate.
SD, standard deviation. yr, years.
Percentages based on total participant number except for * HIV infection status or responding number.
** low level education (< 6 years).BMC Nephrology 2009, 10:18 http://www.biomedcentral.com/1471-2369/10/18
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C. Hypertension and/or Diabetes, and CKD status
Table 4 gives BP control according to JNC VII [18] and
serum glucose levels of the participants according to their
CKD status. CKD patients were much more likely to have
HTN than those without CKD (P = 0.0005). 82% of par-
ticipants with history of DM had elevated fasting serum
glucose levels at screening (≥ 126 mg/dl [≥ 7 mmol/l]),
and 78% of those with history of HTN did not have their
BP controlled to less than 140/90 mmHg. Among individ-
uals with HTN having CKD, 99% received treatment.
However, only 6% of all individuals with HTN had their
BP reduced to lower than 130/80 mmHg and 22% had BP
lower than 140/90 mmHg. The majority of the treated
individuals with HTN were receiving one antihypertensive
medication and, only 23% used Angiotensin-Converting
Enzyme Inhibitors (ACEI).
Furthermore, only 4% of patients with DM and HTN hav-
ing CKD had BP controlled to less than 130/80 mmHg
and ACEI treatment was prescribed in only 29%. Patients
with DM were treated with insulin (53%), oral medica-
tion such as metformin or glibenclamide (41%) or insulin
combined with oral antidiabetic medication (1%). Table
5 summarizes the current problems of CKD, ESRD, and
cost.
D. Determinants of CKD
Determinants of CKD 3+ are displayed in Table 6. HTN
(adjusted OR 3.3, 95% CI 1.7–6.5; P  < 0.001), DM
(adjusted OR 2, 95% CI 1.1–3.8; P = 0.01) and dipstick
proteinuria (adjusted OR 2, 95% CI 1.1–3.6; P = 0.02)
were independent factors associated with CKD 3+.
Table 2: Prevalence of CKD among at-risk population by level of health care.
Stages of CKD/Heath care
(eGFR. ml/min/1.73 m2)
Primary
N = 291 (%)
Secondary
N = 236 (%)
Total
N = 527 (%)
P
1(≥ 90)* 9 (3.1) 13 (5.5) 22 (4.2) 0.25
2 (60 to 89)* 24 (8.3) 8 (3.4) 32 (6.1) 0.03
3a (45 to 59.9) 43 (14.9) 21 (8.9) 64 (12.2) 0.05
3b (30 to 44.9) 23 (8.0) 9 (3.8) 32 (6.1) 0.07
4 (15 to 29.9) 1 (0.3) 9 (3.8) 10 (1.9) 0.007
5 (< 15) 2 (0.7) 28 (11.9) 30 (5.7) < 0.0001
All stages of CKD 102 (35.3) 88 (37.4) 190 (36.2) 0.68
Proteinuria ≥ 300 mg/day 52 (17.9) 47 (19.9) 99 (18.7) 0.6
Values expressed as numbers and proportions in parentheses or mean ± SD, as appropriate.
Percentages based on responding number or total participant number. For three patients, the sample of serum was not properly handled (missing 
data).
* 24-hours urinary protein excretion ≥ 300 mg/day. eGFR based on MDRD study.
CKD is defined as either kidney damage (proteinuria ≥ 300 mg/day) and/or kidney function (< 60 ml/min/1.73 m2).
Table 3: Prevalence of abnormal urinary findings and serum creatinine by K/DOQI stage of CKD.
Abnormalities/eGFR < 15
N = 27 (%)
15–29
N = 10 (%)
30–59
N = 96 (%)
60–89*
N = 32 (%)
≥90*
N = 22 (%)
Dipstick proteinuria 25 (92.6) 8 (88.9) 81 (85.3) 32 (100.0) 22 (100.0)
Proteinuria ≥ 300 mg/day 18 (66.7) 3 (33.3) 24 (25.3) 32 (100.0) 22 (100.0)
Dipstick hematuria 9 (33.3) 3 (33.3) 11 (11.6) 7 (34.3) 3 (13.6)
Dipstick pyuria 4 (14.8) 4 (44.4) 58 (61.0) 21 (65.6) 10 (45.4)
S. creatinine (men >1.6 md/dl/women > 1.4 mg/dl 27 (100.0) 10 (100.0) 53 (55.2) 1 (3.1) 0
Values expressed as numbers and proportions in parentheses or mean ± SD, as appropriate.
* 24-hours urinary protein excretion ≥ 300 mg/day. eGFR based on MDRD study.
CKD is defined either as kidney damage (proteinuria ≥ 300 mg/day) and/or kidney function (< 60 ml/min/1.73 m2).
Percentages based on total number of dipstick proteinuria available (n = 521).
S. creatinine = serum creatinine; SD, standard deviation.BMC Nephrology 2009, 10:18 http://www.biomedcentral.com/1471-2369/10/18
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However, only pulse pressure > 60 mmHg (adjusted OR
1.8, 95% CI 1.03–3.2; P = 0.03) was statistically associated
with the presence of proteinuria in this study.
In patients with DM, increasing age and duration of DM
were associated with reduction of kidney function (as
eGFR MDRD equation < 60 ml/min/1.73 m2) in multiple
linear regression models according to the following equa-
tion:
[eGFR MDRD study equation = 61.6 - 0.12 (age, in years)
- 0.43 (diabetes duration, in years), P = 0.03]. By contrast,
in patients with HTN, no risk factors were associated with
low eGFR in multiple linear regression models.
Discussion
This study documents CKD among at-risk population in
the health system of Kinshasa, a large city in Sub-Saharan
Africa. The overall prevalence of undiagnosed CKD is
high, at 36%. This prevalence is probably not real since it
was based on non validated MDRD study equation. How-
ever, we think that the question of the validity of eGFR
MDRD in Black race is debatable. Indeed, since the MDRD
Study formula has been adequately validated in African
Americans with kidney disease [22], extrapolation to
Black Africans may be justified in view of similar genetic
and physical attributes. But, validation should still be car-
ried out. Nevertheless, the value of 36% is almost triple
the prevalence of CKD in the general population of this
city [4]. Similar trend has been noted in the Kidney Early
Evaluation Program (KEEP) study [23], mainly for CKD
3+. This fact supports the use of targeted screening in iden-
tifying large numbers of subjects at-risk for CKD. It also
confirms that the risk factors for CKD that are encoun-
tered in developed countries are also found in developing
Africa.
Prevalence (%) of CKD among selected populations by stage of CKD Figure 1
Prevalence (%) of CKD among selected populations by stage of CKD. Abbreviations: DMHTN = patients with diabe-
tes and hypertension, HTN = hypertensive, HIV+ = person having human immunodeficiency virus infection antibody positive, 
FHKD = family history of kidney disease; CKD = chronic kidney disease. CKD is defined either kidney damage (proteinuria ≥ 
300 mg/day) or kidney function (eGFR < 60 ml/min/1.73 m2).
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In addition, our survey indicates that one person out of
five in this group has proteinuria, which was occurred at
all stages of CKD. Among individuals classified as having
CKD stage 3, 25% had macroproteinuria. As some authors
[14,24,25] have suggested, those subjects are the groups at
most risk for cardiovascular disease (CVD) and CKD pro-
gression. With proteinuria and eGFR measurements, we
have identify individuals with CKD stage 1 (4% of studied
population) and CKD stage 2 (6%). In fact, identifying
individuals with these earlier stages is of utmost impor-
tance since strong evidence emerge that the renal and car-
diovascular risks that are associated with stage 1 and 2 are
nearly equal to those of stage 3 [14]. Regrettably, in spite
of this prevalence of proteinuria, in most cases it was nei-
ther detected earlier nor correctly managed before this
study was done. Indeed, in almost all centres, 24 hour-
quantitative proteinuria or dipstick proteinuria were not
routinely available outside this study. Qualitative pro-
teinuria was carried out in usual practice using the acetic
acid method, which has limits of sensitivity and specificity
Table 4: Hypertension and/or diabetes, and CKD status.
Clinical features CKD patients Non CKD patients Total P
JNC 7 guidelines
All patients (BP in mmHg)
Normal, < 120 and < 80 52 (27.5) 143 (43.2) 195 (35.5) 0.0005
PreHBP, 120–139 or 80–89 32 (16.9) 56 (19.6) 88 (16.9) 0.5
Stage 1, 140–159 or 90–99 38 (20.1) 72 (21.8) 110 (21.2) 0.7
Stage 2, ≥ 160 or ≥ 100 67 (35.4) 60 (18.1) 127 (24.4) <0.0001
Hypertensives
Antihypertensive drugs
none 1 (1.1) 11 (10.6) 22 (11.2) 0.01
Any treatment 89 (98.9) 93 (89.4) 182 (88.8) 0.01
1 antihypertensive 62 (71.3) 60 (57.7) 122 (62.2) 0.06
mean antihypertensive drugs 1.28 ± 0.5 1.22 ± 0.6 1.25 ± 0.6 0.1
ACEI* 21 (23.3) 33 (31.7) 54 (27.7) 0.2
Normal, < 120 and < 80 7 (5.2) 17 (10.0) 24 (7.9) 0.1
High normal, 120–139 or 80–89 22 (16.4) 21 (12.4) 43 (14.1) 0.4
Stage 1, 140–159 or 90–99 38 (28.4) 72 (42.4) 110 (36.2) 0.01
Stage 2, ≥ 160 or ≥ 110 67 (50.0) 60 (35.3) 127 (41.8) 0.01
< 130/80 8 (6.0) 21 (12.4) 29 (9.5) 0.09
< 125/75 4 (3.0) 11 (6.5) 15 (4.9) 0.2
Serum glucose level (mg/dl)
Diabetics
< 110 14 (12.8) 17 (9.8) 31 (11.0) 0.5
110–125 8 (7.3) 12 (6.9) 20 (7.1) 0.9
≥ 126 87 (79.8) 145 (83.3) 232 (82.0) 0.5
≥ 180 45 (41.3) 91 (52.3) 136 (48.1) 0.09
Values expressed as numbers and proportions in parentheses or mean ± SD, as appropriate.
CKD is defined either kidney damage (proteinuria ≥ 300 mg/day) and/or kidney function (< 60 ml/min/1.73 m2).
Percentages based on responding number, not total participant number.
ACEI: Angiotensin-Converting Enzyme Inhibitors. PreHTN = Prehypertension.
Table 5: Projected Annual cost arterial hypertension, Diabetes and ESRD Treatment.
Medications Cost per patient (US$) Total cost of all patients projected (US$)
Antihypertensive
Thiazide diuretics 100 280 million
Calcium blocker 250 700 million
ACEI 1000 2.8 billion
Antidiabetic
Biguanide-Metformin 200 240 million
Insulin 350 420 million
Renal replacement treatment
Peritoneal dialysis 36,000 ~1.4 billion*
Hemodialysis 63,000 ~2.5 billion*
* Projection was made from about 1% of patients with diabetes or hypertension developing ESRD
ACEI = angiotensin-converting enzyme inhibitors.
ESRD = end stage renal diseaseBMC Nephrology 2009, 10:18 http://www.biomedcentral.com/1471-2369/10/18
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[26]. Furthermore, and until now, in ordinary secondary
care in Kinshasa, renal complications are assessed only by
serum creatinine alone instead of resorting to formula -
based estimates of creatinine clearance or eGFR. Conse-
quently, many cases of CKD could be missed by using the
serum creatinine alone.
In this present study, we found a discrepancy between
prevalence of dipstick positive protein and proteinuria
mainly in CKD stage 3. This difference may be due to the
fact that only patients with dipstick positive protein 3+
were tested for 24-hour proteinuria. It also confirms dif-
ferences in sensitivity and specificity between tests as
reported recently by Konta et al. [27]. In their survey, the
authors have demonstrated that dipstick positive proteins
are more indicative of microalbuminuria than macroalbu-
minuria.
However, despite the fact that dipstick proteinuria has
limited diagnostic value, it is of a great prognostic value.
Indeed, dipstick positive protein has been associated with
increased risk of cardiovascular events, including the
development of HTN [28], DM [29], and ESRD [30]. But
not all studies are in agreement [31] and it is unclear
whether microalbuminuria is a marker of kidney disease
or generalized vascular disease [32].
As expected [33], HTN, DM and proteinuria were inde-
pendently associated with CKD 3+. Inadequate BP and/or
poor glucose control may explain the CKD that we
observed. The lack of BP control shown in our patients
with HTN, of whom 78% were uncontrolled, is a bit
higher than the 73% seen in Americans [34]. In addition,
only 6% of participants with HTN and 4% of patients with
DM and HTN having CKD had their BP controlled to the
JNC VII recommended level of less than 130/80 mmHg
[18]. This level of control is lower than the 20% in the
New Opportunities for Early Renal Intervention by Com-
puterised Assessment study (NEOERICA) [35] and the
11% reported in the National Health and Nutrition Exam-
ination Survey (NHANES III) [34]. It highlights the inad-
equate levels of BP control in this screening population,
placing them at risk for cardiovascular and/or renal
events, particularly ESRD [8] and may thereby increase
medical care costs. Only 23% of all studied population
received treatment to block the renin-angiotensin system.
Certainly, ACEI may be less effective in Blacks, in whom
the incidence of high renin hypertension is lower than in
Caucasian population. However, the African-American
Study of Kidney Disease and Hypertension (AASK) con-
firmed the reno-protective effects of ACEI compared to
calcium blocker in Blacks with hypertensive nephropathy
[36]. Also, in this AASK trial [36], an average of 2.6 drugs
was needed to achieve BP goals, while the average number
of drugs used by patients with HTN in the present survey
was 1.3.
However, a secondary analysis of AASK study [37] com-
paring ACEI versus β blocker and Calcium blocker versus
β blocker have shown that BP control does not always pre-
vent progression of renal failure. These findings suggest
that factors other than BP elevation likely participate in
the progression of ''hypertensive" nephrosclerosis. But, we
note that in this study [37], the authors did not test the
hypothesis that treatment versus no treatment of HTN
preserves kidney function. The bulk of evidence shows
that BP control slows the progression of hypertensive kid-
ney diseases, and control of the BP is not good in Kin-
shasa.
Table 6: Risk factors associated with CKD.
Determinants OR
(univariate analysis)
CI 95% P OR
(multivariate analysis)
CI 95% P
CKD stage ≥ 3
HTN versus no 2.9 1.9 – 4.6 0.001 3.3 1.7 – 6.5 0.001
Pulse pressure > 60 versus < 60 mmHg 2.0 1.3–3.2 0.001 1.09 0.6 – 1.8 0.7
Age ≥ 50 versus <50 years 1.8 1.2–2.7 0.002 1.5 0.9–2.4 0.08
DM versus no 1.5 1.04–2.3 0.04 2.0 1.1–3.8 0.01
Dipstick proteinuria ≥ 1+ versus 0 2.9 1.7–5.1 < 0.0001 2.0 1.1–3.6 0.02
Herbal remedy use versus no 1.7 1.03–2.7 0.002 1.2 0.7–1.9 0.3
24 h- quantitative proteinuria (≥ 300 mg/24 
h)
Pulse pressure > 60 versus < 60 mmHg 2.4 1.5–3.9 < 0.0001 1.8 1.03 – 3.2 0.03
HTN versus no 1.7 1.1–2.8 0.01 1.2 0.7 – 2.2 0.4
DM versus no 1.7 1.05–2.8 0.03 1.4 0.8–2.4 0.1
Abbreviations: CKD 3+ (eGFR < 60 ml/min/1.73 m2), CKD = chronic kidney disease, CI = confidence interval, DM = diabetes, HTN= hypertension.BMC Nephrology 2009, 10:18 http://www.biomedcentral.com/1471-2369/10/18
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HTN was also common with type 2 diabetes, which was
more frequent than type 1 in the present study. In addi-
tion, most patients with DM in this study had poor glu-
cose control. Appropriate management of DM and HTN
are important to both the prevention and control of renal
disease [23]. Awareness by patient and health care pro-
vider will help in this regard, and our study has advanced
that awareness in Kinshasa.
Age and duration of DM also influenced the occurrence of
CKD in this present study.
Duration of DM is well recognized as an important risk
factor for diabetic nephropathy [9]. But duration of HTN
did not have a correlation with low eGFR in this survey.
That fits well with the fact that in most cases of renal dis-
eases, HTN is the result of, rather than the cause of, the
low eGFR. However, we do not know the exact causes of
low eGFR in the subjects of this study.
CKD can also result from transmissible diseases such as
HIV infection. Our observations show that the prevalence
of CKD among HIV positive people is 12%. This value is
lower than the 20% found in Uganda [38] and the 27%
reported in Soweto [39]. It is on the other hand higher
than the 2% [40] and 0.7% [41] described in the USA and
in Ethiopia, respectively. This discrepancy of prevalence
between these studies could be due to the difference in
methodology applied in each survey. It could also reflect
an ethnic disparity [42], or even a socio-economic gradi-
ent. But, it is hard to determine the true CKD prevalence
among HIV population because a validated eGFR method
does not exist in HIV subjects.
Among patients with a family history of kidney disease,
the proportion of CKD was 8%. In addition, while Rami-
rez et al [43] showed that FH-KD was a strong determi-
nant of proteinuria, with OR of 2.5, FH-KD in our survey
was not associated with proteinuria or with reduction of
kidney function. This observation may due to low aware-
ness of CKD and its familial associations by both health
workers and the lay population.
Another preventable risk factor for CKD is the use of
herbal remedies, which was found in our study in univar-
iate analysis but not in multivariate analysis. Others have
reported renal toxicity and other adverse effects of tradi-
tional herbal remedies [44]. We can not state which of the
remedies are nephrotoxic since studies of their composi-
tion are lacking.
Some risk factors for CKD such as smoking or LBW,
reported elsewhere [43], were not observed in the present
study. However, most of our study population did not
have birth certificates or knowledge of their weight at
birth, so the risk of LBW is probably not adequately
assessed in this study. The reason why tobacco use was not
associated with proteinuria remains unclear and deserves
further attention.
An important issue that is not resolved by this study is
how to reach high-risk individuals who do not attend
these clinics as well the problem of payment for antihy-
pertensive and antidiabetic drugs.
We think that our recent model of annual screening for
proteinuria and CKD risk factors [45] combining educa-
tional message, detection and management of risk factor
in general population may contribute partly to reach this
first goal.
However, despite their benefits, treatments of HTN and/
or DM are costly. This limits their use in SSA, where about
half the population lives on less than $ 1 per day [3]. In
Kinshasa the annual cost of drugs for optimal antihyper-
tensives such as thiazide diuretics, calcium blocker, or
ACE inhibitors, ranges from US $ 100, $ 250, and $ 1000
per patient, respectively, as estimated from a weighted
average of wholesale prices for five proprietary products in
the market. In this city, it is currently estimated that there
are 2.8 million hypertensives [4]. Thus, if all hypertensives
were treated with one or more of these drugs we can
project that annual cost for these drugs would be between
$ 280 million and $ 2.8 billion. If the same drugs are used
in combination, the cost of the treatment would be even
higher. In patients with DM, the estimated cost per patient
of oral antidiabetics and insulin are about $ 200 and $
350 per year, respectively. If we extrapolate these figures to
the current 1.2 million diabetics in Kinshasa [4], the
annual cost is over $ 240 million for biguanide-met-
formin and $ 420 million for insulin. The expenditure in
patients with DM and HTN would be even higher. On the
assumption that 1% of the hypertensive or diabetic popu-
lation would evolve to ESRD there would be 28,000
hypertensives and 12,000 diabetics requiring RRT. Hence,
we can project the annual cost for RRT in Kinshasa at
~$1.4 billion for peritoneal dialysis or ~2.5 billion for
hemodialysis. These estimates for the cost of RRT will be
higher if more hypertensives and/or diabetics progress to
ESRD. It is clear that long-term dialysis will not be an
option for most Africans with renal failure, and it is also
likely that the use of anti-hypertensives and better treat-
ment for DM will only reduce, not eliminate, the number
of cases of diabetic and hypertensive nephropathy that
evolve to ESRD. That said, the increased use of anti-hyper-
tensives and better treatments for DM may reduce non-
renal morbidity and mortality, which may make these
treatments worth their expense. Indeed, El-Nahas [1] has
made a case for the cost-effectiveness of screening for
CKD, worldwide, in all populations.BMC Nephrology 2009, 10:18 http://www.biomedcentral.com/1471-2369/10/18
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We believe that use of anti-hypertensives and anti-diabetic
treatment will reduce morbidity and mortality, but the
magnitude of this benefit is not known. Still, in consider-
ation of the combined cost of anti-hypertensive and dia-
betic treatment, as compared to the expense of
cardiovascular disease and chronic dialysis, the cost of
anti-hypertensive and diabetic treatment is cheaper. Thus,
we need the support of the pharmaceutical industry as
well as community support to supply developing coun-
tries with necessary renoprotective and cardioprotective
drugs.
Furthermore, it is noteworthy that this study population
has a very different age distribution from that of the DRC
in general, the subjects of this study having an older age
than that of the general population of Kinshasa. This
could suggest that there will be an increasing number of
such at-risk subjects in the near future. Hence, this situa-
tion is likely to worsen over the next 20 years if no effec-
tive preventive measures are taken.
All health care workers will need to be engaged in this
effort. It is impossible that a few nephrologists would be
able to implement detection and prevention of CKD for
the whole city, let alone the entire DRC. Indeed, in 2004,
the DRC counted only 0.11 physicians per 1000 popula-
tion and 0.52 nurses per 1000 population [46]. Conse-
quently, management of the patients in this country must
be by nurses for primary care and by general practitioners
for secondary care. Adapting K/DOQI guidelines must
account for local conditions and manpower.
Strength and limitation of our study
The strength of our survey is that it includes patients at-
risk for CKD follow-up in multiple centres of primary as
well as secondary health care and that we used a random
sample and standardised methods of data collection.
Already, by doing this study, we have improved awareness
of optimal CKD care in traditional health care system of
Kinshasa.
Our study has certain limitations. It is a cross-sectional
snapshot analysis with 24-hour urinary protein not meas-
ured in every patient and serum creatinine measured only
once. This may overestimate CKD. It has also a relatively
small size, and it relies on the MDRD equation, the vali-
dation of which is lacking among African populations as
well as in those with HIV. Moreover, the inaccuracy of 24
h urine collection may also over or underestimate CKD.
Finally, although all participants were chosen randomly
by the local team, it is possible that the choice was made
among the more affected patients having needed special-
ized opinion.
Conclusion
Despite the above limitations, our findings show the
effectiveness of community based targeted health screen-
ing program, in identifying significant numbers of per-
sons with CKD previously undiagnosed, and also in
finding those with inadequate risk-factor control. This
study suggests that there is a great potential for decreasing
CKD as well as ESRD incidence and cardiovascular mor-
bidity or mortality by optimizing modifiable risk factors
in this high-risk population. It also suggests that the costs
of treating those with CKD may be cost-beneficial, by
averting the morbidity of cardiovascular disease and also
the very high cost of RRT. Furthermore, our study empha-
sizes the urgent need for increased training of generalist
physicians and nurses in CKD prevention programs as
well an active collaboration between traditional health
care and nephrology services.
The establishment of prevention programs in developing
countries is also a political and financial challenge. This
challenge could be taken up by creation of international
funding assistance as exists for HIV or tuberculosis infec-
tion, the goal of which would be to support the program
of prevention of CKD, and some of its risk factors such as
HTN, DM and obesity.
Finally, further study is needed to improve the precision
of these preliminary data and to assess the benefit of anti-
hypertensive such as ACEI on the progression of renal dis-
ease in Black Africans. That is because studies in Afro-
Americans may probably not be directly applicable to
Sub-Saharan Africans and extrapolation must be made
with caution.
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